| Literature DB >> 23648003 |
Thilini Kalugalage1, Chaturaka Rodrigo, Thamal Vithanage, Pranitha Somaratne, H Janaka De Silva, Shiroma Handunnetti, Senaka Rajapakse.
Abstract
BACKGROUND: The relationship between inducible nitric oxide synthatase activity and disease severity in leptospirosis is unclear. Nitric oxide is converted to nitrites and nitrates, thus nitrite and nitrate levels (NOx) in serum are considered surrogate markers for nitric oxide. NOx are excreted through the kidneys, and elimination is diminished in renal impairment. We assessed the correlation of NOx with disease severity in patients with leptospirosis, compared with healthy controls and non-leptospirosis fever patients.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23648003 PMCID: PMC3651868 DOI: 10.1186/1471-2334-13-206
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Comparison of age and gender among the study groups
| Number of patients | 40 | 27 | 18 |
| MAT titre | ≥ 400 | 100-200 | 0 |
| Mean age ± SD (years) | 39.7 ± 14.6 | 38.4 ± 15.2 | 37.8 ± 13.8 |
| Gender (Male:Female) | 19 : 1 | 26 : 1 | 8 : 1 |
Laboratory parameters of mild and sever leptospirosis patients, MAT equivocal patients and non-leptospirosis fever controls (univariate analysis)
| WBC-highest (cells/mm3) | 15461 ± 9625 | 11418 ± 5071 | 12170 ± 3637 | 11650 ± 2703 |
| Platelets-lowest (cells/mm3) | 114714 ± 91166 | 142154 ± 72178 | NA | NA |
| ESR-highest (mm/hour) | 59.8 ± 42.7 | 45.6 ± 41.1 | 47.6 ± 40.8 | 45.3 ± 23.9 |
| Bilirubin-total (μmol/l) | 159.0 ± 140.2* | 49.7 ± 37.2 | 52.1 ± 40.6 | 61.29 ± 69.5 |
| AST (U/L) | 138.6 ± 90.0 | 97.5 ± 75.3 | 140.9 ± 141.7 | 89.8 ± 68.7 |
| ALT (U/L) | 105.4 ± 58.0 | 94.6 ± 63.3 | 89.7 ± 59.9 | 62.4 ± 27.7 |
| Blood urea (mmol/l) | 16.0 ± 8.3* | 5.7 ± 5.4 | 6.7 ± 3.9 | 6.7 ± 4.6 |
| Serum creatinine (μmol/l) | 520.4 ± 200.4* | 113.3 ± 15.6 | 153.6 ± 142.9 | 140.1 ± 82.1 |
† mean ± SD; NA – not available; *differed at a statistically significant level (p<0.001) from patients with mild disease and MAT equivocal patients.
ANOVA post-hoc comparison using Bonferonni correction comparing uncorrected NOx in the different groups
| NLF | MAT eq | -.509167 | 2.661898 | 1.000 |
| Mild lepto | −7.622690 | 3.117296 | .162 | |
| Severe lepto | −18.547372* | 2.682296 | .000 | |
| Controls | 7.444000 | 2.727634 | .075 | |
| MAT equivocal | NLF | .509167 | 2.661898 | 1.000 |
| Mild lepto | −7.113524 | 2.881040 | .152 | |
| Severe lepto | −18.038205* | 2.403658 | .000 | |
| Controls | 7.953167* | 2.454149 | .016 | |
| Mild leptospirosis | NLF | 7.622690 | 3.117296 | .162 |
| MAT eq | 7.113524 | 2.881040 | .152 | |
| Severe lepto | −10.924681* | 2.899897 | .003 | |
| Controls | 15.066690* | 2.941883 | .000 | |
| Severe leptospirosis | NLF | 18.547372* | 2.682296 | .000 |
| MAT eq | 18.038205* | 2.403658 | .000 | |
| Mild lepto | 10.924681* | 2.899897 | .003 | |
| Controls | 25.991372* | 2.476259 | .000 | |
| Healthy Controls | NLF | −7.444000 | 2.727634 | .075 |
| MAT eq | −7.953167* | 2.454149 | .016 | |
| Mild lepto | −15.066690* | 2.941883 | .000 | |
| Severe lepto | −25.991372* | 2.476259 | .000 |
NLF: Non-leptospirosis fever, MAT eq: MAT equivocal patients, lepto: leptospirosis. Sig: significance. * denotes statistically significant differences.
Figure 1Serum NOlevels in different patient groups and healthy controls. NLF: Non-leptospirosis fever; MAT Eq: MAT equivocal patients. lepto: leptospirosis.
NOvalues in the different categories
| Confirmed leptospirosis | 40 | 28.247 | 11.425 | 1.806 |
| Severe leptospirosis | 26 | 32.071 | 11.773 | 2.309 |
| Mild leptospirosis | 14 | 21.146 | 6.441 | 1.722 |
| MAT equivocal | 27 | 14.032 | 7.579 | 1.459 |
| Non-leptospirosis fever | 18 | 13.523 | 11.581 | 2.730 |
| Healthy controls | 23 | 6.078 | 2.802 | 0.572 |
ANOVA post-hoc comparison using Bonferonni correction comparing NOx/creatinine in the different groups
| NLF | MAT eq | -.026593 | .020710 | 1.000 |
| Mild Lepto | -.087484* | .024253 | .005 | |
| Severe lepto | .029598 | .020869 | 1.000 | |
| Controls | .019194 | .021222 | 1.000 | |
| MAT eq | NLF | .026593 | .020710 | 1.000 |
| Mild Lepto | -.060892 | .022415 | .077 | |
| Severe lepto | .056191* | .018701 | .033 | |
| Controls | .045787 | .019094 | .183 | |
| Mild lepto | NLF | .087484* | .024253 | .005 |
| MAT eq | .060892 | .022415 | .077 | |
| Severe lepto | .117082* | .022562 | .000 | |
| Controls | .106679* | .022889 | .000 | |
| Severe lepto | NLF | -.029598 | .020869 | 1.000 |
| MAT eq | -.056191* | .018701 | .033 | |
| Mild Lepto | -.117082* | .022562 | .000 | |
| Controls | -.010404 | .019266 | 1.000 | |
| Controls | NLF | -.019194 | .021222 | 1.000 |
| MAT eq | -.045787 | .019094 | .183 | |
| Mild Lepto | -.106679* | .022889 | .000 | |
| Severe lepto | .010404 | .019266 | 1.000 |
NLF: Non-leptospirosis fever, MAT eq: MAT equivocal patients, lepto: leptospirosis, Sig: significance. * denotes statistically significant differences.
Figure 2Corrected NO(NO/creatinine) in different patient groups and healthy controls. NLF: Non-leptospirosis fever; MAT Eq: MAT equivocal patients. lepto: leptospirosis.
NOx/creatinine levels in the different study groups
| Confirmed leptospirosis | 40 | 0.113 | 0.074 | 0.012 |
| Severe leptospirosis | 26 | 0.072 | 0.042 | 0.008 |
| Mild leptospirosis | 14 | 0.189 | 0.058 | 0.015 |
| MAT equivocal | 27 | 0.128 | 0.096 | 0.018 |
| Non-leptospirosis fever | 18 | 0.101 | 0.085 | 0.020 |
| Healthy controls | 23 | 0.082 | 0.038 | 0.008 |